Laura Chico
Stock Analyst at Wedbush
(1.06)
# 796
Out of 4,667 analysts
203
Total ratings
27.69%
Success rate
-14.01%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics | Maintains: Outperform | $44 → $45 | $31.95 | +40.85% | 9 | Nov 8, 2024 | |
| VIGL Vigil Neuroscience | Maintains: Outperform | $23 → $24 | $3.05 | +686.89% | 8 | Nov 8, 2024 | |
| PEPG PepGen | Maintains: Outperform | $19 → $12 | $4.40 | +172.73% | 9 | Nov 8, 2024 | |
| VERA Vera Therapeutics | Maintains: Neutral | $30 → $38 | $45.75 | -16.94% | 7 | Nov 8, 2024 | |
| ANRO Alto Neuroscience | Downgrades: Neutral | $29 → $4 | $4.27 | -6.32% | 3 | Oct 23, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $9 → $8 | $4.91 | +62.93% | 8 | Oct 9, 2024 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $17 → $25 | $17.86 | +39.98% | 9 | Oct 9, 2024 | |
| LRMR Larimar Therapeutics | Initiates: Outperform | $22 | $6.08 | +261.84% | 1 | Oct 3, 2024 | |
| BIIB Biogen | Maintains: Neutral | $210 → $205 | $156.00 | +31.41% | 16 | Sep 23, 2024 | |
| LBPH Longboard Pharmaceuticals | Maintains: Outperform | $40 → $44 | $59.77 | -26.38% | 7 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $48 | $73.68 | -34.85% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $9.58 | +129.65% | 8 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $4 | $0.70 | +474.30% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $41 | $27.49 | +49.15% | 13 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $49 | $39.34 | +24.56% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $36 | $20.77 | +73.33% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $5.36 | +30.60% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $24.42 | +6.47% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $43 → $46 | $46.40 | -0.86% | 11 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.92 | +123.58% | 13 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $19.79 | +112.23% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $11.31 | +50.31% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $41 | $2.66 | +1,441.35% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $123.29 | +23.29% | 7 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $31 | $20.50 | +51.22% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.99 | +1,006.53% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $1.04 | +669.23% | 1 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $5.48 | -8.76% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $62.56 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $2.01 | +148.76% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $46.83 | +217.10% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $16.08 | +4,377.61% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $15.12 | +1,751.85% | 1 | Apr 21, 2017 |
Edgewise Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $44 → $45
Current: $31.95
Upside: +40.85%
Vigil Neuroscience
Nov 8, 2024
Maintains: Outperform
Price Target: $23 → $24
Current: $3.05
Upside: +686.89%
PepGen
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $4.40
Upside: +172.73%
Vera Therapeutics
Nov 8, 2024
Maintains: Neutral
Price Target: $30 → $38
Current: $45.75
Upside: -16.94%
Alto Neuroscience
Oct 23, 2024
Downgrades: Neutral
Price Target: $29 → $4
Current: $4.27
Upside: -6.32%
Sage Therapeutics
Oct 9, 2024
Maintains: Neutral
Price Target: $9 → $8
Current: $4.91
Upside: +62.93%
Travere Therapeutics
Oct 9, 2024
Maintains: Outperform
Price Target: $17 → $25
Current: $17.86
Upside: +39.98%
Larimar Therapeutics
Oct 3, 2024
Initiates: Outperform
Price Target: $22
Current: $6.08
Upside: +261.84%
Biogen
Sep 23, 2024
Maintains: Neutral
Price Target: $210 → $205
Current: $156.00
Upside: +31.41%
Longboard Pharmaceuticals
Sep 17, 2024
Maintains: Outperform
Price Target: $40 → $44
Current: $59.77
Upside: -26.38%
Aug 14, 2024
Maintains: Neutral
Price Target: $40 → $48
Current: $73.68
Upside: -34.85%
Aug 13, 2024
Reiterates: Outperform
Price Target: $22
Current: $9.58
Upside: +129.65%
Aug 13, 2024
Reiterates: Outperform
Price Target: $4
Current: $0.70
Upside: +474.30%
Aug 9, 2024
Maintains: Neutral
Price Target: $38 → $41
Current: $27.49
Upside: +49.15%
Aug 9, 2024
Maintains: Outperform
Price Target: $50 → $49
Current: $39.34
Upside: +24.56%
Aug 9, 2024
Maintains: Outperform
Price Target: $38 → $36
Current: $20.77
Upside: +73.33%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $5.36
Upside: +30.60%
Aug 2, 2024
Maintains: Outperform
Price Target: $30 → $26
Current: $24.42
Upside: +6.47%
Aug 2, 2024
Maintains: Neutral
Price Target: $43 → $46
Current: $46.40
Upside: -0.86%
Aug 2, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.92
Upside: +123.58%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $19.79
Upside: +112.23%
Jul 11, 2024
Reiterates: Outperform
Price Target: $17
Current: $11.31
Upside: +50.31%
Jun 6, 2024
Reiterates: Outperform
Price Target: $41
Current: $2.66
Upside: +1,441.35%
May 29, 2024
Reiterates: Outperform
Price Target: $152
Current: $123.29
Upside: +23.29%
May 9, 2024
Maintains: Outperform
Price Target: $35 → $31
Current: $20.50
Upside: +51.22%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.99
Upside: +1,006.53%
Apr 5, 2024
Initiates: Outperform
Price Target: $8
Current: $1.04
Upside: +669.23%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $5.48
Upside: -8.76%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $62.56
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $2.01
Upside: +148.76%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $46.83
Upside: +217.10%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $16.08
Upside: +4,377.61%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $15.12
Upside: +1,751.85%